{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T09:25:41Z","timestamp":1787217941318,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-05672-z","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T06:36:40Z","timestamp":1785739000000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The role of the prognostic nutritional index at baseline and follow-up in patients with metastatic prostate cancer"],"prefix":"10.1007","volume":"17","author":[{"given":"Muhammet","family":"Cengiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9133-8602","authenticated-orcid":false,"given":"Ay\u015fe","family":"Nuransoy Cengiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3551-5234","authenticated-orcid":false,"given":"Oktay","family":"Bozkurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5495-7540","authenticated-orcid":false,"given":"Gozde","family":"Erturk Zararsiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8014-4140","authenticated-orcid":false,"given":"Ahmet Kursat","family":"Disli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6494-9088","authenticated-orcid":false,"given":"Ridvan","family":"Gonul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7721-5646","authenticated-orcid":false,"given":"Kamuran","family":"Yuceer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6875-4656","authenticated-orcid":false,"given":"Irfan","family":"Bugday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9260-5454","authenticated-orcid":false,"given":"Aleyna","family":"Erakcao\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1008-2527","authenticated-orcid":false,"given":"Emel","family":"Mutlu Ozkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3737-3420","authenticated-orcid":false,"given":"Mevlude","family":"Inanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0359-0504","authenticated-orcid":false,"given":"Metin","family":"Ozkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"issue":"3","key":"5672_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"5672_CR2","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.eururo.2024.11.013","volume":"87","author":"EJ Schafer","year":"2025","unstructured":"Schafer EJ, Laversanne M, Sung H, Soerjomataram I, Briganti A, Dahut W, et al. Recent patterns and trends in global prostate cancer incidence and mortality: an update. Eur Urol. 2025;87(3):302\u201313.","journal-title":"Eur Urol"},{"issue":"3","key":"5672_CR3","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.eururo.2024.11.013","volume":"87","author":"EJ Schafer","year":"2024","unstructured":"Schafer EJ, Laversanne M, Sung H, Soerjomataram I. Recent patterns and trends in global prostate cancer incidence and mortality: an update. Eur Urol. 2024;87(3):302\u201313. https:\/\/doi.org\/10.1016\/j.eururo.2024.11.013.","journal-title":"Eur Urol"},{"issue":"5","key":"5672_CR4","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1001\/jamaoncol.2022.7762","volume":"9","author":"IB Riaz","year":"2023","unstructured":"Riaz IB, Naqvi SAA, He H, Asghar N, Siddiqi R, Liu H, et al. First-line systemic treatment options for metastatic castration-sensitive prostate cancer: a living systematic review and network meta-analysis. JAMA Oncol. 2023;9(5):635\u201345. https:\/\/doi.org\/10.1001\/jamaoncol.2022.7762.","journal-title":"JAMA Oncol"},{"key":"5672_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.euros.2020.12.006","volume":"24","author":"ME Lendorf","year":"2021","unstructured":"Lendorf ME, Petersen PM, Svendsen AS, Lindberg H, Brasso K. Effectiveness of docetaxel for metastatic hormone-sensitive prostate cancer in clinical practice. Eur Urol Open Sci. 2021;24:25\u201333. https:\/\/doi.org\/10.1016\/j.euros.2020.12.006.","journal-title":"Eur Urol Open Sci"},{"issue":"5","key":"5672_CR6","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1002\/pros.24850","volume":"85","author":"H Kato","year":"2025","unstructured":"Kato H, Goto Y, Kojima S, Onoda Y, Wakai K, Hou K, et al. Time to castration resistance is associated with overall survival even after the achievement of castration resistance in metastatic prostate cancer. Prostate. 2025;85(5):471\u201381.","journal-title":"Prostate"},{"issue":"5","key":"5672_CR7","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424\u201333.","journal-title":"N Engl J Med"},{"issue":"2","key":"5672_CR8","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138\u201348.","journal-title":"N Engl J Med"},{"issue":"6","key":"5672_CR9","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1001\/jamaoncol.2024.0591","volume":"10","author":"M Hussain","year":"2024","unstructured":"Hussain M, Fizazi K, Shore ND, Heidegger I, Smith MR, Tombal B, et al. Metastatic hormone-sensitive prostate cancer and combination treatment outcomes: a review. JAMA Oncol. 2024;10(6):807\u201320. https:\/\/doi.org\/10.1001\/jamaoncol.2024.0591.","journal-title":"JAMA Oncol"},{"issue":"5","key":"5672_CR10","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","volume":"20","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, Tran NP, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20(5):686\u2013700.","journal-title":"Lancet Oncol"},{"key":"5672_CR11","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","volume":"13","author":"K Fizazi","year":"2012","unstructured":"Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al. Articles abiraterone acetate for treatment of metastatic castration-resistant prostate cancer\u202f: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13:983\u201392.","journal-title":"Lancet Oncol"},{"issue":"32","key":"5672_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A. ARCHES\u202f: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer abstract. J Clin Oncol. 2019;37(32):9\u201311.","journal-title":"J Clin Oncol"},{"issue":"11","key":"5672_CR13","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","volume":"36","author":"CE Kyriakopoulos","year":"2018","unstructured":"Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 chaarted trial. J Clin Oncol. 2018;36(11):1080\u20137.","journal-title":"J Clin Oncol"},{"issue":"7","key":"5672_CR14","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1007\/s00432-022-04220-w","volume":"149","author":"M Neuberger","year":"2023","unstructured":"Neuberger M, Goly N, Skladny J, Milczynski V, Wei\u00df C, Wessels F, et al. Systemic inflammatory biomarkers as predictive and prognostic factors in men with metastatic castration-refractory prostate cancer treated with docetaxel therapy: a comprehensive analysis in a German real-world cohort. J Cancer Res Clin Oncol. 2023;149(7):3371\u201381. https:\/\/doi.org\/10.1007\/s00432-022-04220-w.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"5672_CR15","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/s41391-023-00689-9","volume":"27","author":"Y Zheng","year":"2024","unstructured":"Zheng Y, Wang K, Ou Y, Hu X, Wang Z, Wang D, et al. Prognostic value of a baseline prognostic nutritional index for patients with prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2024;27(4):604\u201313.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"8","key":"5672_CR16","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.jgo.2022.06.011","volume":"13","author":"WP Bensken","year":"2022","unstructured":"Bensken WP, Schiltz NK, Warner DF, Kim DH, Wei MY, Qui\u00f1ones AR, et al. Comparing the association between multiple chronic conditions, multimorbidity, frailty, and survival among older patients with cancer. J Geriatr Oncol. 2022;13(8):1244\u201352.","journal-title":"J Geriatr Oncol"},{"issue":"9","key":"5672_CR17","first-page":"1001","volume":"85","author":"T Onodera","year":"1984","unstructured":"Onodera T, Goseki N, Kosaki G. Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients. Nihon Geka Gakkai Zasshi. 1984;85(9):1001\u20135.","journal-title":"Nihon Geka Gakkai Zasshi"},{"issue":"22","key":"5672_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers15225333","volume":"15","author":"T Naiki","year":"2023","unstructured":"Naiki T, Takahara K, Watanabe H, Nakane K, Sugiyama Y, Koie T, et al. The geriatric nutritional risk index predicts prognosis in Japanese patients with LATITUDE high-risk metastatic hormone-sensitive prostate cancer: a multi-center study. Cancers (Basel). 2023;15(22):1\u201312.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"5672_CR19","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/pros.23969","volume":"80","author":"Y Yamada","year":"2020","unstructured":"Yamada Y, Sakamoto S, Rii J, Yamamoto S, Kamada S, Imamura Y, et al. Prognostic value of an inflammatory index for patients with metastatic castration-resistant prostate cancer. Prostate. 2020;80(7):559\u201369.","journal-title":"Prostate"},{"issue":"1","key":"5672_CR20","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s12672-025-02084-3","volume":"16","author":"M Uzun","year":"2025","unstructured":"Uzun M, Gokcek S, Kaya E, Semiz HS. The prognostic role of systemic immune-inflammation index, SII, in Metastatic Castration-Resistant Prostate Cancer patients. Discov Oncol. 2025;16(1):317.","journal-title":"Discov Oncol"},{"key":"5672_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2024.1436063","author":"SY Li","year":"2024","unstructured":"Li SY, Wan LL, Liu YF, Li YW, Huang X, Liu RJ. Prognostic value of three clinical nutrition scoring system (NRI, PNI, and CONUT) in elderly patients with prostate cancer. Front Nutr. 2024. https:\/\/doi.org\/10.3389\/fnut.2024.1436063.","journal-title":"Front Nutr"},{"issue":"5","key":"5672_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102142","volume":"22","author":"E Tobing","year":"2024","unstructured":"Tobing E, Tansol C, Tania C, Sihombing AT. Prognostic nutritional index (PNI) as independent predictor of poor survival in prostate cancer: a systematic review and meta-analysis. Clin Genitourin Cancer. 2024;22(5):102142. https:\/\/doi.org\/10.1016\/j.clgc.2024.102142.","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"5672_CR23","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"5672_CR24","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.eururo.2025.01.010","volume":"87","author":"AA Azad","year":"2025","unstructured":"Azad AA, Kostos L, Agarwal N, Attard G, Davis ID, Dorff T, et al. Combination therapies in locally advanced and metastatic hormone-sensitive prostate cancer. Eur Urol. 2025;87(4):455\u201367.","journal-title":"Eur Urol"},{"issue":"10323","key":"5672_CR25","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","volume":"399","author":"G Attard","year":"2022","unstructured":"Attard G, Murphy L, Clarke NW, Cross W, Jones RJ, Parker CC, et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet. 2022;399(10323):447\u201360.","journal-title":"Lancet"},{"key":"5672_CR26","doi-asserted-by":"publisher","first-page":"1324181","DOI":"10.3389\/fonc.2024.1324181","volume":"14","author":"Y Lu","year":"2024","unstructured":"Lu Y, Jiang J, Yang G, Ding H, Zheng Q, Ji L, et al. Comparative effectiveness of multiple androgen receptor signaling inhibitor medicines with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a study in the real world. Front Oncol. 2024;14:1324181.","journal-title":"Front Oncol"},{"issue":"9","key":"5672_CR27","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","volume":"31","author":"C Parker","year":"2020","unstructured":"Parker C, Castro E, Fizazi K, Heidenreich A, Ost P, Procopio G, et al. Prostate cancer\u202f: ESMO clinical practice guidelines for diagnosis, treatment. Ann Oncol. 2020;31(9):1119\u201334. https:\/\/doi.org\/10.1016\/j.annonc.2020.06.011.","journal-title":"Ann Oncol"},{"key":"5672_CR28","doi-asserted-by":"publisher","first-page":"656","DOI":"10.3390\/nu16050656","volume":"16","author":"M Litwiniuk","year":"2024","unstructured":"Litwiniuk M, Brajer-luftmann B, Mardas M. Influence of androgen deprivation therapy on the development of sarcopenia in patients with prostate cancer\u202f: a systematic review. Nutrients. 2024;16:656.","journal-title":"Nutrients"},{"key":"5672_CR29","first-page":"1","volume":"16","author":"L Jie","year":"2025","unstructured":"Jie L, Lin Y, Chiang P, Lin J, Jan Y, Tasai Wei-kung CY. Androgen deprivation therapy \u2013 induced muscle loss and fat gain predict cardiovascular events in prostate cancer patients. J Cachexia Sarcopenia Muscle Orig. 2025;16:1\u201312.","journal-title":"J Cachexia Sarcopenia Muscle Orig."},{"issue":"3","key":"5672_CR30","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/pros.24096","volume":"81","author":"J-M Liu","year":"2021","unstructured":"Liu J-M, Lin C-C, Chen M-F, Liu K-L, Lin C-F, Chen T-H, et al. Risk of major adverse cardiovascular events among second-line hormonal therapy for metastatic castration-resistant prostate cancer: a real-world evidence study. Prostate. 2021;81(3):194\u2013201.","journal-title":"Prostate"},{"issue":"6","key":"5672_CR31","first-page":"1","volume":"61","author":"H Taban","year":"2025","unstructured":"Taban H, Erman M, Guven DC, Aktas BY, Yilmaz F, Ya\u015far S, et al. Prognostic nutritional index and a blood-based prognostic tool in prostate cancer treated with abiraterone. Enzalutamide or Cabazitaxel Med. 2025;61(6):1\u201314.","journal-title":"Enzalutamide or Cabazitaxel Med"},{"issue":"7","key":"5672_CR32","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/pros.24876","volume":"85","author":"MB Hacioglu","year":"2025","unstructured":"Hacioglu MB, Kucukarda A, Gokmen I, Gurbuz AF, Araz M, Kahvecioglu FA, et al. Prognostic nutritional index as a biomarker in metastatic hormone-sensitive prostate cancer: impact on survival and treatment optimization. Prostate. 2025;85(7):693\u2013702.","journal-title":"Prostate"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-05672-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05672-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05672-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T08:49:04Z","timestamp":1787215744000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-05672-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5672"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-05672-z","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]},"assertion":[{"value":"15 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study protocol was approved by the Erciyes University Health Sciences Research Ethics Committee (Decision No. 2025\/139), with a waiver of informed consent due to its retrospective nature. All procedures were conducted in accordance with the ethical standards of institutional and national research committees on human experimentation and with the 1975 Declaration of Helsinki, as revised in 2024.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have read and approved the final version of the manuscript.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1225"}}